References
- Steurer-Stey C, Bachmann LM, Steurer J, et al. Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review. Chest 2004;126:1645-55
- Adriana Roży JC-W. Bacterial immunostimulants—mechanism of action and clinical application in respiratory diseases. Pneumonologiai Alergologia Polska 2008;76:353-9
- Benedetto FD, Sevieri G. Prevention of respiratory tract infections with bacterial lysate OM-85 bronchomunal in children and adults: a state of the art. Multidiscip Resp Med 2013;8:33
- Cao PP, Li HB, Wang BF, et al. Distinct immunopathologic characteristics of various types of chronicrhinosinusitis in adult Chinese. J Allergy ClinImmunol 2009;124:478-84, 484.e1-2
- Heintz B, Schlenter WW, Kirsten R, et al. Clinical efficacy of Broncho-Vaxom in adult patients with chronic purulent sinusitis – a multi-centric, placebo-controlled, double-blind study. Int J Clin Pharm Therapy Toxicol 1989;27:530-4
- Zagar S, Löfler-Badzek D. Broncho-Vaxom in children with rhinosinusitis: a double-blind clinical trial. ORL J Otorhinolaryngol Relat Spec 1988;50:397-404
- Huber M, Mossmann H, Bessler WG. Th1-orientated immunological properties of the bacterial extract OM-85-BV. Eur J Med Res 2005;10:209-17
- Emmerich B, Emslander HP, Milatovic D, et al. Effects of a bacterial extract on local immunity of the lung in patients with chronic bronchitis. Lung 1990;168(Suppl):726-31
- Parola C, Salogni L, Vaira X, et al. Selective activation of human dendritic cells by OM-85 through a NF-kB and MAPK dependent pathway. PLoS One 2013;8:e82867
- Gomez Barreto D, De la Torre O, Alvarez A, et al. Safety and efficacy of OM-85-BV plus amoxicillin/clavulanate in the treatment of subacute sinusitis and the prevention of recurrent infections in children. Allergol Immunopathol (Madrid) 1998;26:17-22
- Soler M, Mutterlein R, Cozma G; Swiss-German OM-85 Study Group. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration 2007;74:26-32
- Bergemann R, Brandt A, Zoellner U, et al. Preventive treatment of chronic bronchitis: a meta-analysis of clinical trials with a bacterial extract (OM-85 BV) and a cost-effectiveness analysis. Monaldi Arch Chest Dis 1994;49:302-7
- Collet JP, Ducruet T, Haider S, et al. Economic impact of using an immunostimulating agent to prevent severe acute exacerbations in patients with chronic obstructive pulmonary disease. Can Resp J 2001;8:27-33
- Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med 2007;176:753-60
- Fang X, Wang X, Bai C. COPD in China: the burden and importance of proper management. Chest 2011;139:920-9
- Pessey JJ, Megas F, Arnould B, et al. Prevention of recurrent rhinopharyngitis in at-risk children in France: a cost-effectiveness model for a nonspecific immunostimulating bacterial extract (OM-85 BV). Pharmacoeconomics 2003;21:1053-68